Related Experiment Videos
[Clinical studies of cefpodoxime proxetil in respiratory tract infections]
S Odagiri1, K Matsunaga, K Suzuki
1Department of Respiratory Disease, Kanagawa Prefectual Nagahama Hospital.
Abstract:
Twelve patients with respiratory tract infections were treated with cefpodoxime proxetil (CS-807, CPDX-PR), a new cephem antibiotic. It was given orally at a dose of 200 mg 2 times a day for 4 approximately 15 days. Its clinical effects were evaluated as excellent in 1 case, good in 9 cases and poor in 2 cases. The efficacy rate was 83.3%. Its bacteriological effects were evaluated as eradication in 5 strains and decrement in 1 strain. The eradication rate was 83.3%. No adverse reactions and disorder of laboratory findings due to CPDX-PR were observed.
Insights
Cefpodoxime proxetil, an oral cephem antibiotic, demonstrated an 83.3% clinical efficacy rate in treating respiratory tract infections. This new antibiotic showed significant bacteriological eradication and was well-tolerated with no adverse effects observed in patients.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Respiratory tract infections (RTIs) pose a significant public health challenge.
- Novel antimicrobial agents are crucial for combating bacterial resistance.
- Cephem antibiotics offer a valuable class of therapeutic options.
Observation:
- Twelve patients diagnosed with RTIs were enrolled in the study.
- Patients received oral cefpodoxime proxetil (CPDX-PR) at 200 mg twice daily for approximately 15 days.
- Clinical and bacteriological outcomes were systematically monitored.
Findings:
- Cefpodoxime proxetil achieved an overall clinical efficacy rate of 83.3% (1 excellent, 9 good, 2 poor).
- Bacteriological evaluation showed a 83.3% eradication rate against targeted strains.
- No adverse reactions or laboratory abnormalities were associated with CPDX-PR treatment.
Implications:
- Cefpodoxime proxetil presents a promising oral treatment option for respiratory tract infections.
- The favorable efficacy and safety profile support its potential clinical utility.
- Further research may explore its role in broader infectious disease management.